Biopharma firm ANGLE signs supplier deal with AstraZeneca
Liquid biopsy company ANGLE has signed a supplier agreement with AstraZeneca.
The Guildford firm has penned a deal to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR.
Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response.
Assay development will take place in ANGLE's laboratories in Guildford,, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.
ANGLE Chief Executive Officer, Andrew Newland, said: "This is ANGLE's second large pharma company agreement of 2024 as we look to drive a significant expansion of the pharma services business. It demonstrates the importance of CTC analysis and is a validation of ANGLE's Parsortix system. ANGLE is also working to expand its DDR work with other large pharma customers and continues to generate significant new customer interest through its business development activity."
